Abvc biopharma announces collaboration with merdury biopharma for new product development and commercialization

Fremont, ca, june 06, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (“abvc” or the “company”) (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that biokey, a wholly-owned subsidiary of the company based in fremont, california, signed a collaborative agreement with merdury biopharma on june 1st, 2023 to co-develop new drug products leveraging merdury's stackdosetm platform technology.
ABVC Ratings Summary
ABVC Quant Ranking